Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.57 |
| ▸ | BRAF | P15056 | 10/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.55 |
| ▸ | RAF1 | P04049 | 5/20 | 0.55 |
| ▸ | CSF1R | P07333 | 4/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282170 | 0.86 | KDR (0.62) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL10073792 | 0.84 | CSF1R (0.73) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL281946 | 0.80 | SRC (0.49) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL282549 | 0.79 | CSF1R (0.72) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL282116 | 0.77 | PDGFRA (0.66) | KDRCSF1RPDGFRAPDGFRBKIT | |
| SCHEMBL281954 | 0.76 | CSF1R (0.70) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL282308 | 0.76 | CSF1R (0.70) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL17668250 | 0.75 | BRAF (0.81) | KDRBRAFRAF1PDGFRAPDGFRB | |
| SCHEMBL2848857 | 0.72 | MAPK14 (0.73) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL5202980 | 0.71 | KDR (0.85) | KDRBRAFMAPK14TNNI3KRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | claimed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | KDR 3633/4885BRAF 1216/4885MAPK14 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.